谷氨酰胺强化治疗对危重症病人临床结局影响的系统性研究  

The impact of glutamine on clinical outcomes in critical and surgical patients:A systematic review and Meta-analysis

作　　者：李明泉[1] 舒磊[1] 王晓霞[1] 王昕怡[1] 刘增军[1] 赵明[1] 

机构地区：[1]南京军区南京总医院内分泌科干部病区,江苏南京210002

出　　处：《肠外与肠内营养》2014年第2期101-105,共5页Parenteral & Enteral Nutrition

摘　　要：目的：系统评价谷氨酰胺（Gln）强化治疗对危重症病人预后的影响. 方法：检索数据库,鉴定随机对照试验（RCT）,采用Rev Man 5.2软件进行Meta分析. 结果：共51项RCT符合全部纳入标准.病死率：合并相对危险度（RR）为0.88,95％置信区间（CI）为0.73～ 1.06,Gln组死亡风险与对照组比较,差异无统计学意义（P＞0.05）.院内感染：合并RR为0.82,95％ CI为0.74 ～0.91（P ＜0.05）.住院时间：与对照组比较,Gln组住院时间约缩短1.55 d,95％CI [-1.92,-1.19] （P＜0.01）. 结论：对危重症病人,Gln强化治疗能降低院内感染的发生率,缩短住院时间,有利于预后.Objective： To assess the safety and validity of glutamine supplementation in critical and surgical patients. Methods ： We searched eligible literatures and abstracted data with RevMan 5.2 for Meta-analysis. Results： 51 studies were included in final analysis. When aggregated the data about mortality the supplementation of glutamine was associated with a risk ratio （RR） of 0.88, 95% CI[0.73, 1.06 ] （P = 0.08）. Meanwhile, there was a lower risk of infection in glutamine group and the RR was 0.82, 95 % CI [ 0.74, 0.91] （P 〈 0.01 ）. With respect to hospital length of stay, pooled weight mean difference （WMD） was - 1.55, 95% CI [ - 1.92, - 1.19 ] （P 〈 0.01 ）. Conclusion ： Glutamine supplementation in severely ill patients may reduce infections and hospital length of stay.

关 键 词：谷氨酰胺 营养支持 临床结局 系统评价 

分 类 号：R459.3[医药卫生—治疗学]